SINTEF Collaboration for Chronic Wound Management

Argent Biopharma Limited

21 August 2024

 

21 August 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

Strategic Collaboration with SINTEF for Advanced Chronic Wound Management

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, is pleased to announce a strategic collaboration with SINTEF, one of Europe's largest independent research organisations, to address the critical and unmet clinical challenge of chronic wound management, through nano-formulations as part of the Company's ongoing expansion into new therapeutic areas.

Argent Biopharma hopes that this collaboration with SINTEF will lead to significant advancements in the treatment of chronic wounds, ultimately improving the quality of life for patients suffering from this challenging condition. The Company looks forward to updating shareholders as the project progresses.

Project overview

Chronic wounds represent a significant clinical issue globally, causing extreme patient suffering and affecting substantial numbers of individuals. These wounds present complex challenges, including severe symptoms, antibiotic- resistant infections, impenetrable biofilms, and deteriorating local tissue health.

Argent BioPharma intends for this study to address multiple facets of this complex condition as detailed below:

·    Identification and Selection of Novel Anti-Microbial Active Ingredients:

o  Experiments performed with SINTEF will initially focus on identifying and selecting the antimicrobial activities of a range of repurposed polypharmacological agents endowed with multiple medically beneficial activities.

·    Improving Local Tissue Health and Symptomatic Relief:

o  SINTEF will further investigate the chosen range of active ingredients for their anti-biofilm, skin-health modifying and symptom alleviating functions.

·    Optimizing nano-formulations of the selected active ingredients to enhance the derived medical benefits:

o  The composition of the particles will be modified in response to the efficacy observed in the course of development, simultaneously with modification of their additional pharmacological features.

The collaboration will be targeting chronic wound infections with an array of various nano-encapsulated active ingredients. The precise selection and dosing of these active ingredients will be methodically evaluated. The greater part of the ingredients have not served previously as designated anti-microbial agents, thus aligning with antimicrobial stewardship.

A significant aspect of this project is the design of nano-formulations for the selected agents which are intended to be identified in the initial screening experiments. Nano-formulation is expected to enhance the pharmacological characteristics and efficacy of the resulting preparation via improved drug delivery, increased penetration through biofilms, and sustained release of active compounds, thereby addressing the challenges posed by antibiotic resistance and local tissue health deterioration.

All costs applicable to the project will be incurred by Argent BioPharma, although, it is not anticipated that these costs will have a material impact on the Company's ongoing expenses. Additionally, Argent BioPharma will retain ownership of all project results, including any intellectual property developed.

-Ends-

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]

Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]

About Argent BioPharma

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system ("CNS") and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

About SINTEF

SINTEF is one of Europe's largest research institutes, with multidisciplinary expertise within technology, natural sciences and social sciences. SINTEF is an independent foundation which, since 1950, has created innovation through development and research assignments for business and the public sector at home and abroad.

 

END